

**EISAI TO PRESENT LATEST DATA OF LEMBOREXANT
AT 35th ANNUAL SLEEP MEETING (SLEEP2021)**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO®) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).

Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Poster Presentations

Asset in Product/Development Poster Number	Poster Title
Lemborexant #335	Evaluation of Dose Transition From Zolpidem to Lemborexant Across 14 Weeks: Results From a Multicenter Open-label Pilot Study
Lemborexant #336	Effect of Lemborexant versus Placebo and Zolpidem on REM Sleep by Quarter Night Intervals in Older Adults with Insomnia Disorder
Lemborexant #337	A Multicenter Open-label Pilot Study Evaluating Next-Dose Transition From Zolpidem to Lemborexant: Analysis of Female Subgroup
Lemborexant #338	How Much Improvement in the Insomnia Severity Index Is Associated With a Positive Impact of a Patient's Insomnia Medication?
Lemborexant #339	Long-term Perception of Medication Effectiveness in Subjects Receiving Lemborexant for up to 12 Months

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

<Notes to editors>

1. About Lemborexant (product name: DAYVIGO®)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. In June 2020, lemborexant was launched under the product name DAYVIGO in the U.S. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance; and in July 2020, it was launched under the product name DAYVIGO in Japan for the treatment of insomnia. The agent was approved for the treatment of insomnia in Canada and Hong Kong, while new drug applications seeking approval for the treatment of insomnia were submitted in Australia, Asia and other countries.